Business Wire

NY-COMPLYADVANTAGE

Share
ComplyAdvantage Extends Series C Round To $70 Million With New Goldman Sachs Investment

ComplyAdvantage , a global data technology company transforming financial crime detection, today announced a new investment by the Growth Equity team in Goldman Sachs Asset Management. The terms of the transaction were not disclosed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005678/en/

The investment is an extension to the company’s oversubscribed Series C funding announced in July 2020. Goldman Sachs Asset Management joins a growing list of the company’s world-class investors including the Ontario Teachers’ Pension Plan Board, Index Ventures, and Balderton Capital.

ComplyAdvantage will use this new investment to build on the rapid growth it has experienced to date and cement its position as a critical part of the value chain for companies managing evolving risks around anti-money laundering (AML), know your customer (KYC) processes and broader financial crime.

The company also has been establishing itself as the global partner of choice for high growth companies including the U.S. crypto exchange Gemini , the Australian payment app Beem It and OakNorth Bank , one of the most successful challenger banks in the U.K.

In addition, the company also announced the availability of a new program called ComplyLaunch that provides free access to the company's award-winning AML tools and education for startups, helping them to protect to the integrity of their businesses by reducing the threat of financial crime

“We've seen first-hand the compelling benefits that ComplyAdvantage offers across a range of portfolio companies,” said James Hayward, Managing Director in the Growth Equity team at Goldman Sachs Asset Management. “The company brings clear value to its clients and has grown at an impressive rate. We are excited to support the business as it continues to scale rapidly and help companies of all stages manage these critical risks.”

“Financial services innovation is the catalyst for massive business transformation. Companies need a hyper-scale AML and risk solution as a financial crime deterrent,” said Charles Delingpole, founder and CEO of ComplyAdvantage. “Goldman Sachs Asset Management is a great partner for ComplyAdvantage because they recognize the power of intelligent AML and risk detection not only to fortify businesses but also to help them introduce new services to market with greater confidence and integrity.”

Due to the unprecedented acceleration of digital transformation, rapidly growing fintechs and corporates alike need a partner that can keep pace with innovation and market opportunities in the compliance space. Given the growing volume, velocity and complexity of financial crimes, the traditional methods of human analysts reviewing batched data are no longer viable in many cases.

Instead, what’s needed is an intelligent approach to AML and risk mitigation using massive amounts of data that’s contextualized with machine learning logic to deliver insights with greater accuracy in real-time and at scale. ComplyAdvantage’s hyper-scale AML and risk detection technology does exactly that, so the data never grows stale. Companies future proof their risk management solution and can grow with confidence.

ComplyAdvantage offers a true hyperscale financial risk insight and AML data solution that leverages machine learning and natural language processing to help regulated organizations manage their risk obligations and prevent financial crime. The company’s proprietary database is derived from millions of data points that provide dynamic, real-time insights across sanctions, watchlists, politically exposed persons, and negative news. This reduces dependence on manual review processes and legacy databases by up to 80% and improves how companies screen and monitor clients and transactions.

About The Growth Equity team in Goldman Sachs Asset Management

Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment banking, securities and investment management firm. The Growth Equity team is the dedicated growth equity team within Goldman Sachs Asset Management, with over 25 years of investing history, over $8 billion of assets under management, and 9 offices globally. To read more, visit: https://growth.gs.com/homepage.html

About ComplyAdvantage

ComplyAdvantage is the financial industry’s leading source of AI-driven financial crime risk data and detection technology. ComplyAdvantage’s mission is to neutralize the risk of money laundering, terrorist financing, corruption, and other financial crime. More than 500 enterprises in 75 countries rely on ComplyAdvantage to understand the risk of who they’re doing business with through the world's only global, real-time database of people and companies. The company actively identifies tens of thousands of risk events from millions of structured and unstructured data points every single day.

ComplyAdvantage has four global hubs located in New York, London, Singapore and Cluj-Napoca and is backed by Ontario Teachers’, Index Ventures and Balderton Capital. Learn more at complyadvantage.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 07:01:00 CET | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual

NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release

NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu

Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release

Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum

Argo Infrastructure Partners Increases Ownership and Capital Commitment to TierPoint9.12.2025 23:00:00 CET | Press release

The latest investment brings total capital formation under Argo ownership to $3 billionDemonstrates a growing commitment to TierPoint from existing and new capital partners of Argo supporting the continued growth of its leading data center platform Argo Infrastructure Partners, LP (“Argo”), an established mid-market asset manager of essential infrastructure assets in North America, today announced it has acquired on behalf of its managed funds the equity interests of the majority of minority shareholders in TierPoint. The transaction reflects Argo’s continued conviction in TierPoint’s strategy and growth potential during a period of accelerating demand for TierPoint’s enterprise-class data center services. Since Argo’s initial investment in 2020, $3 billion of capital has been raised to fund growth and reduce TierPoint’s cost of capital by terming out debt facilities. The investment capital has advanced TierPoint’s market position as a data center services provider to enterprises, gove

Venture Global Announces Closing of $3,000,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC9.12.2025 22:30:00 CET | Press release

Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $3,000,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 6.125% senior secured notes due 2030 in an aggregate principal amount of $1,750,000,000 (the “2030 Notes”) and (ii) a series of 6.500% senior secured notes due 2034 in an aggregate principal amount of $1,250,000,000 (the “2034 Notes” and, together with the 2030 Notes, the “Notes”). The 2030 Notes will mature on December 15, 2030, and the 2034 Notes will mature on June 15, 2034. Venture Global had previously announced the issuance of $2,500,000,000 of senior secured notes by VGPL on April 21, 2025, and $4,000,000,000 of senior secured notes by VGPL on July 3, 2025 (collectively, the “Existing Notes”), bringing the combined aggregate amount of senior secured notes issued by VGPL to $9,500,000,000 since the project

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye